Table 1 Study participant characteristics
From: Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon
| Â | SSc-RP, n = 13 | HC, n = 12 |
|---|---|---|
Age (years), mean ± SD or as indicated | 49.3 (± 19.9) | 39.5 (± 11.9) |
Sex (n (%), female) | 12 (92.3) | 11 |
SSc disease duration | 10.9 ± 5.2 |  |
SSc subtype (n (%)) | ||
 •LcSSc | 9 (69.2) |  |
Modified Rodnan skin score | 6.1 ± 4.5 |  |
Nailfold capillaroscopy (n (%)) | ||
 •Early | 1 (8) |  |
 •Active | 3 (23) |  |
 •Late | 3 (23) |  |
 •N/A | 6 (46) |  |
Serum autoantibodies (n (%)) | ||
 •ANA | 10 (76.9) |  |
 •Anticentromere | 4 (30.8) |  |
 •Anti-topoisomerase I | 5 (38.5) |  |
 •Anti-RNA polymerase III | 1 (7.7) |  |
RP attack rate/2 weeks | 31.5 ± 29.1 |  |
Telangiectasias (n (%)) | 12 (92.3) | Â |
Any clinically evident calcinosis cutis (n (%)) | 1 (7.7) | Â |
Medications (n (%)) | ||
 •Calcium channel blocker | 8 (61.5) |  |
 •Aspirin | 2 (15.4) |  |
 •Statin | 5 (38.5) |  |
 •Mycophenolate mofetil | 2 (15.4) |  |
 •Mycophenolic acid | 1 (7.7) |  |